COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS Russian patent published in 2012 - IPC C07D401/10 C07D401/14 C07D413/06 C07D413/14 C07D417/14 C07D487/04 C07D491/48 A61K31/44 A61K31/496 A61K31/4965 A61P3/10 

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula I:

or pharmaceutically acceptable salts thereof, in which Q is a divalent or trivalent radical selected from C_6-10aryl and heteroaryl; where said aryl or heteroaryl in Q is optionally substituted up to 3 times with radicals independently selected from halogen, C_1-6 alkyl, C_1-6 alkyl substituted with halogen, C_1-6 alkoxy group, C_1-6 alkoxy group substituted with halogen, -C(O)R₂₀ and -C(O)OR₂₀; where R₂₀ is selected from hydrogen and C_1-6 alkyl; and where optionally, the carbon atom neighbouring W₂ can be bonded through CR₃₁ or O with a carbon atom of Q to form a 5-member ring condensed with A and Q rings; where R₃₁ is selected from hydrogen and C_1-6 alkyl; W₁ and W₂ are independently selected from CR₂₁ and N; where R₂₁ is selected from hydrogen and -C(O)OR₂₅; where R₂₅ denotes hydrogen; ring A can contain up to 2 carbon ring atoms substituted with a group selected from -C(O)-, -C(S)- and -C(=NOR₃₀)- and can be partially unsaturated and contain up to 2 double bonds; where R₃₀ denotes hydrogen ; L is selected from C_1-6alkylene, C_2-6alkenylene, -OC(O)(CH₂)_n-, -NR₂₆(CH₂)n- and -O(CH₂)_n-; where R₂₆ is selected from hydrogen and C_1-6 alkyl; where n is selected from 0, 1, 2, 3 and 4; q is selected from 0 and 1; t₁, t₂, t₃ and t₄ are each independently selected from 0, 1 and 2; R₁ is selected from -X₁S(O)_0-2X₂R_6a, -X₁S(O)_0-2X₂OR_6a, -X₁S(O)_0-2X₂C(O)R_6a, -X₁S(O)_0-2X₂C(O)OR_6a, -X₁S(O)_0-2X₂OC(O)R_6a and -X₁S(O)_0-2NR_6aR_6b; where X₁ is selected from a bond, O, NR_7a and C_1-4alkylene; where R_7a is selected from hydrogen and C_1-6alkyl; X₂ is selected from a bond and C_1-6alkylene; R_6a is selected from hydrogen, cyanogroup, halogen, C_1-6alkyl, C_2-6alkenyl, C_6-10aryl, heteroaryl, heterocycloalkyl and C₃-₈cycloalkyl; where said aryl, heteroaryl, cycloalkyl and heterocycloalkyl in R_6a is optionally substituted with 1-3 radicals independently selected from hydroxy group, halogen, C_1-6alkyl, C_1-6alkyl substituted with a cyano group, C_1-6alkoxy group and C_6-10aryl-C_1-4alkoxy group; and R_6b is selected from hydrogen and C_1-6alkyl; R₃ is selected from hydrogen, halogen, hydroxy group, C_1-6alkyl, C_1-6alkyl substituted with halogen, C_1-6alkyl substituted with a hydroxy group, C_1-6alkoxy group, C_1-6alkoxy group substituted with halogen, -C(O)R₂₃ and -C(O)OR₂₃; where R₂₃ is selected from hydrogen and C_1-6alkyl; R₄ is selected from R₈ and -C(O)OR₈; where R₈ is selected from C_1-6alkyl, heteroaryl, C_3-8cycloalkyl and heterocycloalkyl; where said heteroaryl, cycloalkyl or heterocycloalkyl in R₈ is optionally substituted with 1-3 radicals independently selected from halogen, C_1-6alkyl, C_3-8cycloalkyl and C_1-6alkyl substituted with halogen; R₅ is selected from hydrogen, C_1-6alkyl substituted with a hydroxy group, and a C_1-6alkoxy group; heteroaryl denotes a monocyclic or condensed bicyclic aromatic ring complex containing 5-9 carbon atoms in the ring, where one or more ring members are heteroatoms selected from nitrogen, oxygen and sulphur, and heterocycloalkyl denotes a saturated monocyclic 4-6-member ring in which one or more said carbon atoms in the ring are substituted with a group selected from -O-, -S- and -NR-, where R denotes a bond, hydrogen or C_1-6alkyl. The invention also relates to pharmaceutical compositions containing said compounds, and methods of using said compounds to treat or prevent diseases or disorders associated with GPR119 activity, such as obesity, type 1 diabetes, type 2 sugar diabetes, hyperlipidemia, type 1 autopathic diabetes, latent autoimmune diabetes in adults, type 2 early diabetes, child atypical diabetes, adult diabetes in children, malnutrition-associated diabetes and diabetes in pregnant women.

EFFECT: improved properties of compounds.

27 cl